

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
JAN 17 2002
TECH CENTER 1600/2900

Re application of: Ni et al.

Application No: 09/109,864


Art Unit: 1646

Filed: July 6, 1998

Examiner: Ulm, J.

For: Objectin 11

Attorney Docket No.: PF354P1



SUBMISSION UNDER 37 C.F.R. § 1.114
AND RESPONSE TO PAPER NO. 22

24/D
M.G.J
1/17/02

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action mailed October 12, 2001, and in accordance with 37 C.F.R. § 1.114, please enter the following amendments and consider the remarks below. Applicants submit concurrently herewith: (a) a Request for Continued Examination under 37 C.F.R. § 1.114; (b) a Fee Transmittal Sheet accompanied by the appropriate fee; (c) a Second Supplemental Information Disclosure Statement with revised form PTO/SB/08 and a copies of the cited references A1, C34, and C35; and (d) Version with Markings to Show Changes Made.

In the Claims

Please cancel claims 44-65 and 154-157, without prejudice or disclaimer.

Please amend claims 66, 69, 72-74, 121, 136 and 145, as follows:

D1 66. (Twice Amended) The isolated nucleic acid molecule of claim 167 comprising a heterologous polynucleotide sequence.

D2 69. (Once Amended) A recombinant vector comprising the isolated nucleic acid molecule of claim 167.

01/15/2002 JADD01 00000121 083425 09109864

02-FE:102 840.00 CH

D3 72. (Twice Amended) A recombinant host cell comprising the nucleic acid molecule of claim 167 wherein the polynucleotide sequence is operably associated with a